This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

HIV disease resulting in multiple diseases classified elsewhere달리 분류된 다발성 질환을 유발한 인체면역결핍바이러스병

Contents and key points
ItemDetails
A. Classification codesICD-10: B22.7 (HIV disease resulting in multiple diseases classified elsewhere) | Special Copayment Reduction: V103 (severe intractable disease, 5 years)
B. SynonymsHIV disease resulting in multiple diseases classified elsewhere; HIV disease resulting in multiple conditions; Advanced HIV disease with multiple comorbidities
C. Adult onsetLikelihood of adult onset: very high — B22.7 is a residual code applied when multiple diseases classified elsewhere (opportunistic infections, tumors, etc.) occur simultaneously or sequentially because of HIV infection. It is used when multiple AIDS complications overlap in adults who are untreated with ART or have insufficiently restored immunity.
1. HistoryThe ICD-10 B22 category is "HIV disease resulting in other specified conditions classified elsewhere," and B22.7 is the code for classifying the co-occurrence of multiple diseases within it. It arose from the need to code complex states in which HIV infection simultaneously causes damage to multiple organs.
2. CausesProgressive immunosuppression due to HIV infection. As the CD4+ T-cell count decreases, multiple opportunistic infections, AIDS-defining tumors, and other HIV-related complications occur simultaneously. Prolonged HIV infection and lack of ART treatment underlie the simultaneous occurrence of multiple complications.
3. GeneticsNot a hereditary disease. Host immune genetic factors (HLA, CCR5, and CCR2 polymorphisms) influence the rate of immune decline and the pattern of complications. The simultaneous occurrence of multiple complications depends on the severity of immunosuppression rather than on a genetic basis.
4. General epidemiologyMultiple AIDS-defining illnesses occur simultaneously in about 30–50% of patients at the AIDS stage before ART. Simultaneous occurrence of multiple opportunistic infections is most common at CD4 <50/μL. This pattern has decreased markedly since ART.
5. PathophysiologyWhen the CD4+ T-cell count falls past the threshold (below 50/μL), the risk of simultaneous occurrence of multiple opportunistic infections rises sharply. Each pathogen independently causes disease in a different organ system, and their interaction accelerates immune depletion.
6. SymptomsOverlap of diverse symptoms involving multiple organ systems simultaneously. Fever, weight loss, dyspnea, neurological symptoms, visual disturbance, diarrhea, etc. appear at the same time. The combination of symptom patterns of each complication complicates diagnosis.
7. SignsMultisystem signs: pulmonary infiltrates, neurological abnormalities, fundus findings, abdominal masses, and skin lesions appear simultaneously. Extremely low CD4 count (10–50/μL), HIV RNA remaining at a high level. Signs of different organ systems overlap, forming a complex clinical picture.
8. ScreeningSystematic opportunistic infection screening in all HIV-infected individuals with CD4 <50/μL (PCP, MAC, CMV, tuberculosis, cryptococcus). Comprehensive evaluation including fundus examination, chest CT, abdominal ultrasound, brain MRI, and blood and lumbar puncture cultures.
9. DiagnosisEstablish an independent diagnosis for each complication. Confirm HIV infection + confirm the simultaneous presence of multiple conditions classified elsewhere. Code each individual disease code together with the B22.7 code to reflect the whole clinical situation.
10. TreatmentImmediate ART initiation. Concurrent treatment of each complication (PCP: TMP-SMX; MAC: clarithromycin + ethambutol; CMV: ganciclovir; cryptococcus: amphotericin B → fluconazole). Thorough management of drug interactions. Multidisciplinary approach within an intensive care system.
11. PrognosisSimultaneous occurrence of multiple AIDS complications is an indicator of poor prognosis. Median survival before ART was several months. Even after ART, short-term mortality is high when multiple complications occur with a very low CD4. Early aggressive intervention improves prognosis.
12. PreventionPrevent severe immunosuppression through early HIV diagnosis and ART. Prophylactic treatment of opportunistic infections by CD4 level. CD4 <200: PCP prophylaxis (TMP-SMX). CD4 <50: MAC prophylaxis (azithromycin). Monitoring of general condition and early intervention.
13. ReferencesIncludes 10 key references

1. History

The ICD-10 code B22.7 is "HIV disease resulting in multiple diseases classified elsewhere," a residual classification code for coding states in which multiple diseases classified elsewhere occur simultaneously or sequentially because of HIV infection.

As the HIV/AIDS epidemic progressed, complex clinical states in which multiple opportunistic infections and complications occur simultaneously, rather than a single AIDS-defining illness, were commonly observed. From the early days of the AIDS epidemic in the early 1980s, cases in which Pneumocystis pneumonia, Kaposi's sarcoma, and cryptococcal meningitis occurred simultaneously were reported, reflecting an extreme state of immunosuppression.

When the WHO developed ICD-10 and established the B20–B24 classification system, the need was recognized for a code reflecting the simultaneous occurrence of multiple complications in addition to individual codes for single complications. "Multiple" codes were also included in each subcategory, such as B20.7 (multiple infections) and B21.7 (multiple malignant neoplasms), and B22.7 covers multiple diseases classified elsewhere in the "other" category.

Typical clinical situations in which B22.7 applies are cases in which, because of HIV infection, (1) encephalopathy (B22.0) and wasting syndrome (B22.2), (2) lymphoid interstitial pneumonitis (B22.1) and encephalopathy (B22.0), or (3) multiple complications belonging to the B22 category are diagnosed simultaneously. Also, when complications under B22.x and other B20.x and B21.x codes overlap, multiple coding including B22.7 is performed.

As the survival of HIV-infected individuals has lengthened since ART, the concept of "multiple chronic complications" has become more important. Today, not only multiple occurrences of AIDS-defining illnesses but also "multimorbidity," in which cardiovascular disease, kidney disease, liver disease, neurocognitive disorder, and so on occur simultaneously in HIV-infected individuals, has emerged as a core clinical challenge.

2. Causes

Multiple HIV-related diseases classified under B22.7 occur when progressive immunosuppression from HIV infection simultaneously affects multiple organ systems.

Severe immunosuppression: when the CD4+ T-cell count falls below 50/μL, the risk of simultaneous occurrence of multiple opportunistic infections rises sharply. A typical pattern is simultaneous or sequential appearance of PCP, MAC, CMV retinitis, and cryptococcal meningitis. Each opportunistic pathogen has a different CD4 threshold, but when CD4 falls extremely low, below 50, all defenses against opportunistic infections collapse.

Delayed diagnosis or lack of access to treatment: in HIV-infected individuals without access to ART, multiple complications accumulate over an average course of 10 years from infection diagnosis to AIDS manifestation. Delayed ART access, socioeconomic vulnerability, and poor access to health care in developing countries are the main background to the simultaneous occurrence of multiple complications.

Immune reconstitution inflammatory syndrome (IRIS): during immune recovery after ART initiation, IRIS can occur in which multiple previously undiagnosed opportunistic infections become clinically manifest. Especially when ART is started at a very low CD4 count, a complex situation arises in which IRIS to several opportunistic infections appears simultaneously.

Direct multi-organ damage by HIV: besides CD4+ T cells, HIV directly infects the central nervous system (microglia), kidney (glomerular epithelial cells), heart (cardiomyocytes), and lungs (alveolar macrophages), causing multi-organ dysfunction. Simultaneous manifestation of HIV-associated nephropathy (HIVAN), HIV-associated cardiomyopathy, and HIV-associated encephalopathy falls under this.

3. Genetics

Multiple HIV-related diseases classified under B22.7 are themselves not hereditary diseases. However, host genetic factors influence the rate of progression of HIV infection and the pattern of development of specific complications.

Immune progression genes: individuals carrying HLA-B*57:01 or HLA-B*27:05 tend to have slow progression of HIV infection and delayed development of AIDS complications. Conversely, those carrying HLA-B*35:01 or HLA-B*35:03 have faster immune progression, and multiple complications may occur earlier.

CCR5-Δ32 mutation: CCR5-Δ32 homozygotes are resistant to HIV infection itself. Heterozygotes delay the progression of HIV infection, so AIDS complications occur later. However, once infected, the pattern of multiple complications depends on the CD4 level rather than on CCR5 genotype.

Immune response gene polymorphisms: regulatory polymorphisms of IL-10 and TGF-β determine the intensity of immune activation in HIV infection. Excessive immune activation accelerates immune depletion and raises the risk of multiple complications. Polymorphisms of innate immune restriction factors such as TRIM5α and APOBEC3G also affect the ability to suppress HIV replication.

Opportunistic infection susceptibility genes: FCGR3A polymorphisms associated with susceptibility to cryptococcal meningitis and MBL2 polymorphisms associated with the occurrence of PCP influence the pattern of development of specific opportunistic infectious complications. Simultaneous occurrence of multiple opportunistic infections may be the result of complex interactions among several susceptibility genes.

4. General epidemiology

The epidemiology of the simultaneous occurrence of multiple AIDS complications classified under B22.7 is closely related to ART availability.

Epidemiology before ART: before the introduction of ART, a substantial number of patients at the AIDS stage developed multiple AIDS-defining illnesses simultaneously or sequentially. According to US CDC surveillance data, two or more AIDS-defining illnesses were recorded in about 30–50% of patients diagnosed with AIDS. Simultaneous diagnosis of MAC, CMV retinitis, and PCP was particularly common in patients with CD4 <50/μL.

Epidemiology after ART: after the introduction of ART, the simultaneous occurrence of multiple AIDS-defining illnesses has decreased markedly in developed countries. However, multiple complications still occur in patients who start ART late or have poor treatment adherence. Since the 2010s in high-income countries, "multiple occurrence of non-AIDS complications (multimorbidity)" has become a more common clinical problem than "AIDS-defining complications."

Situation in low-income countries: in sub-Saharan Africa and South Asia, simultaneous occurrence of multiple AIDS complications remains high owing to delayed ART access. Multiple co-infections of tuberculosis with other opportunistic infections are especially common, and cases of tuberculosis + MAC and tuberculosis + PCP co-infection have been reported. In these regions, relatively many clinical cases are coded B22.7.

Epidemiology in Korea: in Korea, simultaneous occurrence of multiple AIDS-defining illnesses has been uncommon since the spread of ART. However, multiple complications are still reported in late-diagnosed HIV-infected individuals (late presenters, first diagnosed with CD4 <200/μL). According to KDCA data, about 20–30% of newly diagnosed HIV cases in Korea are first diagnosed with CD4 <200/μL.

5. Pathophysiology

The pathogenesis of multiple HIV-related diseases classified under B22.7 is a process in which immune depletion from HIV infection simultaneously destroys multiple defense mechanisms.

Threshold effect of CD4+ T-cell decline: the risk of each opportunistic infection increases stepwise with CD4 level. CD4 200–500/μL: oral candidiasis, herpes zoster, bacterial infections. CD4 100–200/μL: PCP, advanced Kaposi's sarcoma. CD4 50–100/μL: toxoplasmosis, cryptococcal meningitis. CD4 <50/μL: disseminated MAC infection, CMV retinitis, leishmaniasis. When CD4 falls below 50, all of these thresholds are crossed simultaneously, so multiple opportunistic infections can occur at the same time.

Direct multi-organ infection by HIV: through monocytes/macrophages, HIV invades various organs (brain, lung, kidney, heart, liver) and causes direct tissue damage. HIV-associated nephropathy (HIVAN), HIV-associated cardiomyopathy, and HIV-associated encephalopathy can progress simultaneously. Such direct multi-organ HIV damage occurs independently of opportunistic infections and creates a clinical situation that falls under the B22.7 classification.

Interaction of multiple opportunistic infections: there is a mutually reinforcing phenomenon in which one opportunistic infection promotes the occurrence of another. CMV infection promotes HIV replication and accelerates CD4 decline. Disseminated MAC infection causes systemic immune activation, further reducing defense against other opportunistic infections. Tuberculosis activates HIV replication and accelerates AIDS progression.

Multiple manifestations in immune reconstitution inflammatory syndrome (IRIS): during immune recovery after ART initiation, paradoxical IRIS occurs in which multiple previously asymptomatic opportunistic infections become clinically apparent simultaneously. In particular, when MAC IRIS, cryptococcal IRIS, and tuberculosis IRIS occur at the same time, application of the B22.7 code is considered.

6. Symptoms

The clinical symptoms of the B22.7 state are very complex, with the symptoms of each simultaneously occurring complication overlapping.

Common systemic symptoms: high fever (38.5°C or above), chills, night sweats, extreme fatigue and weakness, and rapid weight loss commonly appear. Anorexia, nausea, and generalized weakness accompany. These systemic symptoms reflect simultaneous activation of multiple complications.

Pulmonary symptoms: cough (PCP: dry cough; pulmonary tuberculosis/MAC: productive cough), dyspnea, and chest pain occur. When PCP, pulmonary tuberculosis, MAC lung involvement, and CMV pneumonia coexist, mixed respiratory symptoms appear.

Neurological symptoms: headache (cryptococcal meningitis, CMV encephalitis, HIV encephalopathy, etc.), altered consciousness, cognitive decline, visual disturbance (CMV retinitis), and focal neurological deficits (toxoplasma brain abscess) appear in various forms. Interpreting symptoms is difficult when multiple central nervous system complications are present at the same time.

Gastrointestinal symptoms: chronic diarrhea, abdominal pain, and nausea and vomiting are frequent. CMV colitis, MAC gastrointestinal involvement, cryptosporidiosis, and Candida esophagitis can occur simultaneously.

Skin and mucosal symptoms: multiple skin and mucosal lesions are observed, such as Kaposi's sarcoma skin lesions, herpes zoster rash, oral and esophageal candidiasis, and mucosal ulcers due to CMV.

7. Signs

Vital signs: high fever (38.5–40°C), tachycardia, tachypnea, and hypoxemia (SpO₂ <90%) are common. In severe patients, hypotension and a sepsis-like pattern may appear.

Chest findings: in PCP, abnormal findings on chest auscultation are uncommon, but in tuberculosis or MAC lung involvement, localized crackles or bronchial breath sounds may be heard. On chest X-ray/CT, various lesions appear simultaneously, such as bilateral interstitial infiltrates (PCP), upper-lobe cavities (tuberculosis), multiple nodules (MAC/pulmonary dissemination of cryptococcus), and pleural effusion (tuberculosis, lymphoma).

Neurological findings: various neurological abnormalities may be observed simultaneously, such as signs of meningeal irritation (cryptococcal meningitis, tuberculous meningitis), focal neurological deficits (toxoplasma brain abscess, CMV encephalitis), cognitive decline (HIV encephalopathy), and visual field defects (CMV retinitis).

Abdominal findings: hepatosplenomegaly, abdominal lymphadenopathy (disseminated MAC infection, lymphoma), and ascites (tuberculous peritonitis) may appear.

Hematological findings: CD4+ T-cell count <50/μL (extremely low), high HIV RNA level. Pancytopenia (bone marrow involvement by MAC or tuberculosis), elevated serum LDH (PCP, lymphoma), positive serum β-D-glucan (PCP, fungal infection), cryptococcal serum antigen, positive CMV pp65 antigenemia.

8. Screening

Systematic screening for multiple opportunistic infections should be performed in HIV-infected individuals with severe immunosuppression (CD4 <50/μL).

Screening for lung infection: chest X-ray is performed as the basic screening. If abnormal, HRCT is added. Serum β-D-glucan (PCP screening), PCR/immunofluorescence testing for PCP on induced sputum or BAL. Tuberculosis IGRA (QuantiFERON) or tuberculin test (caution: false negatives are possible at CD4 <200). Blood MAC PCR (performed at CD4 <50).

Screening for central nervous system infection: if there are headaches or neurological symptoms, brain MRI (contrast-enhanced) is performed first. If brain MRI is normal or lumbar puncture is safe, cerebrospinal fluid (CSF) tests: India ink stain (cryptococcus), cryptococcal antigen, CMV PCR, EBV PCR (differentiating PCNSL), HIV RNA, tuberculosis PCR, toxoplasma PCR.

Ophthalmologic screening: a dilated fundus examination to screen for CMV retinitis is recommended in all patients with CD4 <50/μL. Regular eye examinations are needed even without symptoms.

Systemic screening: blood cultures (including bacterial and fungal). Serum cryptococcal antigen (CRAG). CMV pp65 antigenemia or CMV DNA PCR. Serum toxoplasma antibody (IgG). Abdominal ultrasound (MAC dissemination, lymphadenopathy, hepatosplenomegaly).

9. Diagnosis

Diagnosis of multiple HIV-related diseases classified under B22.7 consists of establishing an individual diagnosis for each complication and synthesizing them.

Coding principle: the B22.7 code is applied when multiple diseases belonging to the B22 category or classified elsewhere are present simultaneously because of HIV infection. The code of each individual complication is coded together with the B22.7 code to reflect the entire clinical situation. Example: B22.7 + B44 (aspergillosis) + A31.2 (disseminated MAC infection) + G05.2 (CMV encephalitis).

Individual diagnosis of each complication: PCP: identification of Pneumocystis jirovecii in induced sputum or BAL (Giemsa, immunofluorescence, PCR). MAC: isolation of Mycobacterium avium complex from blood, BAL, or tissue culture. CMV: serum pp65 antigenemia, positive CMV DNA PCR, intranuclear inclusion bodies on histopathology. Cryptococcus: positive cryptococcal antigen in CSF or serum, positive CSF India ink stain or culture. Toxoplasma: positive serum IgG + imaging findings (multiple contrast-enhancing brain lesions) + response to TMP-SMX treatment.

Comprehensive diagnostic approach: when simultaneous occurrence of multiple complications is suspected, rapid multisystem evaluation is needed. Diagnosis is established stepwise by setting diagnostic priorities (the most life-threatening complication first). Diagnostic testing and empirical treatment are often carried out in parallel.

10. Treatment

Treatment of the multiple AIDS complications classified under B22.7 is based on immediate ART initiation, with standard treatment for each complication applied simultaneously or sequentially.

Timing of ART initiation: when multiple opportunistic infections occur simultaneously, the timing of ART initiation differs according to each complication. Cryptococcal meningitis: start ART after a delay of at least 2–10 weeks to reduce the risk of IRIS. With tuberculosis: if CD4 <50, start ART within 2 weeks after starting antituberculosis treatment. Most other opportunistic infections: start ART as soon as possible (within 2–4 weeks). In life-threatening situations, consider immediate ART.

Treatment protocols for multiple infections: PCP: TMP-SMX 15–20 mg/kg/day (as TMP) for 21 days, with steroids added when CD4 <200. Disseminated MAC infection: clarithromycin 500 mg twice daily + ethambutol 15 mg/kg/day (± rifabutin 300 mg/day). CMV retinitis/visceral infection: ganciclovir 5 mg/kg IV twice daily for 14–21 days, then valganciclovir 900 mg/day maintenance. Cryptococcal meningitis: liposomal amphotericin B 0.7–1 mg/kg/day + flucytosine 100 mg/kg/day for 2 weeks → fluconazole 400 mg/day for 8 weeks → 200 mg/day maintenance. Tuberculosis: isoniazid + rifampin + ethambutol + pyrazinamide for the initial 2 months → isoniazid + rifampin for 4 months (standard 6-month regimen).

Management of drug interactions: rifampin has serious drug interactions with many ART drugs (PIs, INSTIs), so substitute rifabutin for rifampin or take the interactions into account when selecting ART. TMP-SMX carries a risk of nephrotoxicity and bone marrow suppression, and its nephrotoxicity may overlap with that of ART drugs (especially TAF/TDF).

Intensive care and multidisciplinary approach: patients with simultaneous multiple AIDS complications need multidisciplinary consultation among HIV medicine, infectious diseases, neurology, ophthalmology, pulmonology, and so on. Severely ill patients should be considered for intensive care unit (ICU) admission. Nutritional support, fluid therapy, and pain management are provided in parallel.

11. Prognosis

The prognosis of simultaneous multiple AIDS complications classified under B22.7 is markedly worse than that of a single complication.

Short-term mortality: before ART, 6-month mortality in patients with simultaneous multiple AIDS complications reached 50–70%. Even after ART, short-term mortality is high at 20–40% when multiple complications occur at CD4 <50/μL. The prognosis is particularly poor when cryptococcal meningitis occurs together with PCP or tuberculosis.

ART response and prognosis: if HIV RNA is suppressed and CD4 recovers in response to ART, the long-term prognosis of multiple complications improves greatly. Once CD4 recovers to 200/μL or above, recurrence of most opportunistic infections can be prevented. However, central nervous system complications (HIV encephalopathy, CMV encephalitis, neurological sequelae after cryptococcal meningitis) may persist even after CD4 recovery.

Long-term prognostic factors: poor prognostic factors: CD4 <25/μL at diagnosis, multiple central nervous system complications, poor response to treatment of opportunistic infections, poor ART adherence, lack of social support. Good prognostic factors: early ART initiation, treatment response, CD4 recovery, social support.

12. Prevention

Early HIV diagnosis and ART: early diagnosis of HIV infection and immediate ART initiation fundamentally prevent the occurrence of multiple complications. Maintaining CD4 at 200/μL or above through ART prevents most AIDS-defining opportunistic infections.

Prophylactic treatment by CD4 level: CD4 <200/μL: TMP-SMX (or atovaquone/pentamidine) — prevention of PCP and toxoplasmosis. CD4 <100/μL: fluconazole (cryptococcal prevention, optional). CD4 <50/μL: azithromycin (1200 mg/week) or clarithromycin — prevention of disseminated MAC infection. In CD4 <50 patients who are CMV IgG negative, use seronegative or irradiated blood products.

Regular monitoring: early detection in HIV-infected individuals with a low CD4 count through regular fundus examination (CMV retinitis), chest X-ray, blood MAC PCR, and serum cryptococcal antigen testing. Check ART adherence and confirm viral suppression.

Patient education: HIV-infected individuals are taught to visit a medical institution immediately if symptoms of opportunistic infection (fever, headache, visual disturbance, dyspnea, diarrhea) appear. Continuing education is needed on the importance of ART adherence and maintaining prophylactic treatment.

13. References

  1. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR Recomm Rep. 2009;58(RR-4):1-207. PMID: 19357635
  2. Dworkin MS, Hanson DL, Kaplan JE, Jones JL, Ward JW. Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds. J Infect Dis. 2000;182(2):611-615. PMID: 10915095
  3. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13(14):1933-1942. PMID: 10513653
  4. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS. 2005;19(11):1113-1124. PMID: 16003094
  5. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS. 2004;18(12):1615-1627. PMID: 15280772
  6. Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002;81(3):213-227. PMID: 12004233
  7. Masur H, Brooks JT, Benson CA, et al. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(9):1308-1311. PMID: 24647015
  8. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487-2498. PMID: 24963568
  9. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4(5):e5575. PMID: 19440326
  10. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14(4):281-290. PMID: 24602844